Reports Q2 revenue $5.8M vs. $4.5M last year. “Biofrontera has always been a leader in innovation in PDT, and with advancements expected in multiple ongoing clinical studies for Ameluz, we are positioned for significant market expansion and revenue potential. In addition to the recent progress in ongoing clinical studies, I am proud of our team now beginning work on an early prototype of a portable PDT lamp, which has the potential not only to expand the use of Ameluz-PDT to physician offices with space limitations, but also to provide our sales force with a new selling proposition that can be easily transported and demonstrated to prospective customers,” said Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BFRI:
- Biofrontera announces last patient enrolled in Phase 3 study of Ameluz-PDT
- BFRI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biofrontera Inc. sees 2023 revenue growth at least 25% vs. 2022
- Biofrontera Inc. reports preliminary Q2 revenues $5.7M-$5.9M
- Biofrontera Inc. appoints Heikki Lanckriet to board of directors